Nanobiotix S.A. (FRA:5NRA)
Germany · Delayed Price · Currency is EUR | Market Cap | 1.39B +919.8% |
| Revenue (ttm) | 32.59M |
| Net Income | -23.96M |
| EPS | -0.50 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 0 |
| Open | 28.60 |
| Previous Close | 27.40 |
| Day's Range | 28.40 - 28.60 |
| 52-Week Range | 2.80 - 35.00 |
| Beta | n/a |
| RSI | 52.83 |
| Earnings Date | Mar 31, 2026 |
About Nanobiotix
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBT... [Read more]
Financial Performance
Financial StatementsNews
Nanobiotix Announces Positive Preclinical Data For Nanoprimer In LNP-DNA Delivery
(RTTNews) - Nanobiotix S.A.(NBTX), a late-stage clinical biotechnology company, announced on Monday preclinical data for the Nanoprimer platform in sequence with lipid nanoparticle-delivered recombina...
Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With Nanoprimer Technology
Preclinical evaluation in mice assessed the potential of the Nanobiotix Nanoprimer to overcome common barriers faced by lipid nanoparticle(“LNP”)-delivered therapies related to rapid liver clearance P...
Voting Rights and Shares Capital of the Company
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) In accordance with...
Nanobiotix FY25 Net Loss Narrows; Expects Cash Runway Through Early 2028; Stock Down
(RTTNews) - Nanobiotix S.A. (NBTX), a late-clinical-stage biotechnology company, reported financial results for the year ended December 31, 2025, reflecting a narrower net loss and provided cash runwa...
NANOBIOTIX Provides Business Update and Reports Full Year 2025 Financial Results
Global development program for JNJ-1900 (NBTXR3) proceeded as planned, building toward opportunity to address one of the largest untapped markets in oncology through lead programs in head and neck can...
NANOBIOTIX to Announce Fourth Quarter and Full Year 2025 Operational and Financial Update on March 31st, 2026
Conference call and webcast scheduled for Wednesday, April 1st, 2026, at 8:00 am EDT / 2:00 pm CEST Conference call and webcast scheduled for Wednesday, April 1st, 2026, at 8:00 am EDT / 2:00 pm CEST
Cancer Drug Developer Nanobiotix Denies Any Active Takeover Process
The stock's movement follows a statement clarifying that there is no ongoing process or assessment for a takeover, which has helped to stabilize investor sentiment as broader markets are experiencing ...
Nanobiotix (NBTX) Addresses Takeover Rumors
Nanobiotix (NBTX) Addresses Takeover Rumors
Nanobiotix Clarifies About Recent Media Speculations Regarding Potential Takeover, Stock Up
(RTTNews) - Nanobiotix S.A. (NBTX) issued a statement on Wednesday in response to recent media speculation concerning intentions for a potential public takeover.
NANOBIOTIX Statement Regarding Recent Media Speculation
PARIS and CAMBRIDGE, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approa...
Voting Rights and Shares Capital of the Company
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
NANOBIOTIX to Participate in Investor Conferences in March
PARIS and CAMBRIDGE, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approac...
Voting Rights and Shares Capital of the Company
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
Nanobiotix (NBTX) Sees Significant Price Target Increase by Guggenheim | NBTX Stock News
Nanobiotix (NBTX) Sees Significant Price Target Increase by Guggenheim | NBTX Stock News
Voting Rights and Shares Capital of the Company
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
Voting Rights and Shares Capital of the Company
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
NANOBIOTIX to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris
PARIS and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering physics-based appro...
Nanobiotix Provides Third Quarter 2025 Operational and Financial Update Along With 2026 Clinical Outlook
PARIS and CAMBRIDGE, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering physics-based appro...
Biotech Stock Nanobiotix (NBTX) Is Up 660% This Year -- Here's Why the Rally Could Continue
Nanobiotix is a small French biotechnology company. It has secured financing from Johnson & Johnson and elsewhere.
NANOBIOTIX Announces Curadigm Nanoprimer Platform Advancements With Updated Plans for Internal Pipeline Development and External Collaborations
PARIS and CAMBRIDGE, Mass., Nov. 13, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering physics-based approa...
NANOBIOTIX to Participate in Investor Conferences the Week of November 10th
PARIS and CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approac...
Nanobiotix (NBTX) Secures $71M Financing Deal with HealthCare Royalty
Nanobiotix (NBTX) Secures $71M Financing Deal with HealthCare Royalty
NANOBIOTIX Announces Strategic Royalty Monetization Agreement With Healthcare Royalty for up to $71 Million and Extends Cash Runway Toward Long-Term Growth
PARIS and CAMBRIDGE, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering physics-based approa...
Nanobiotix (NBTX) Sees Stock Rise on Promising Cancer Drug Trial Results
Nanobiotix (NBTX) Sees Stock Rise on Promising Cancer Drug Trial Results
Top 2 Health Care Stocks That May Keep You Up At Night This Month
As of Oct. 2, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.